Drug-Drug Interaction Study: ASP2151 and Ritonavir
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to
contracting other infections because of their compromised immune system. As HIV patients will
be taking drugs to treat the virus this study aims to see if ASP2151 would interact with one
of the drugs that is commonly prescribed to HIV patients (ritonavir).